Express News | The concept of innovative drugs showed active performance, with Guangshengtang's stock price surging over 10%.

BreakingsApr 29 09:50

Tibet Pharmaceutical: First Quarter Report for 2026

SZSIApr 29 00:00 · Announcements

Tibet Pharmaceutical 2026 First Quarter Report

SZSIApr 29 00:00 · Announcements

Citi: Maintains 'Buy' Rating for Kangzhe Pharmaceuticals, Raises Target Price to HKD 17.5

Citi issued a research report maintaining a 'Buy' rating for CMS Pharmaceuticals (00867). Based on management’s latest guidance for rapid growth in innovative drugs, the bank raised its revenue forecasts for 2026 and 2027 by 1% and 4%, respectively, and increased its earnings per share forecasts by 1% and 13%. The target price was raised from HKD 16.6 to HKD 17.5 to reflect accelerated growth. Revenue for 2025 is projected to increase by 9.9% year-on-year to CNY 8.212 billion, in line with the bank’s and market expectations. Net profit fell by 8.1% year-on-year to CNY 1.489 billion, which is 12% and 11% below the bank’s and market expectations, mainly due to factors related to Tibet.

Sina HK StocksMar 18 12:06

Tibet Pharmaceutical: Tibet Pharmaceutical\'s 2025 Annual Report

SZSIMar 13 00:00 · Announcements

Tibet Pharmaceutical: Summary of Tibet Pharmaceutical\'s 2025 Annual Report

SZSIMar 13 00:00 · Announcements